Self-Amplifying RNA Therapy Shows Promise for Heart Attack Recovery in Preclinical Studies
Key Insights
Researchers developed a novel intramuscular injection using self-amplifying RNA to boost production of ANP, a heart-protective hormone, for sustained cardiac repair following myocardial infarction.
In mouse models, the single-dose therapy improved left ventricular ejection fraction from 20% to 40% by day 28, while also reducing fibrosis and infarct size compared to controls.
The treatment demonstrated efficacy across multiple challenging conditions including aged mice, atherosclerosis models, and metabolic syndrome, though earlier intervention proved more effective than delayed treatment.
Researchers have developed an innovative approach to heart attack recovery using self-amplifying RNA technology that could transform post-myocardial infarction treatment. Published in Science, the study demonstrates how a single intramuscular injection can enhance the heart's natural healing mechanisms by boosting production of a protective hormone for weeks.
The experimental therapy centers on atrial natriuretic peptide (ANP), a hormone naturally involved in cardiovascular homeostasis. While the body increases ANP levels after heart attack, adult hearts don't produce sufficient quantities to drive robust repair, according to the research team led by Dr. Ke Huang from Texas A&M University's Irma Lerma Rangel College of Pharmacy.
Enhanced Hormone Production Through Novel RNA Platform
The treatment utilizes self-amplifying RNA (saRNA) packaged in lipid nanoparticles, carrying instructions for the Nppa (search) gene that encodes pro-ANP. Unlike conventional mRNA, saRNA can briefly replicate itself within cells, extending protein production duration significantly.
"This technology gives us a more efficient way to help the body make what it needs, when it needs it," Huang explained. "A single dose can create a sustained effect, and that's something we simply couldn't achieve with older approaches."
The researchers compared delivery methods in mice and found intramuscular injection superior to intravenous or subcutaneous routes. Intramuscular delivery maintained reporter activity for at least four weeks while confining expression to injected hindlimb muscles without detectable leakage to major organs like liver or spleen.
Significant Cardiac Function Improvements
In mouse models of acute myocardial infarction, animals receiving the injection on the same day as left anterior descending artery ligation showed remarkable recovery. By day 28, treated hearts achieved left ventricular ejection fraction of 40% compared to approximately 20% in control groups receiving phosphate-buffered saline or control RNA nanoparticles.
Additional benefits included thicker ventricular walls, reduced chamber dilation, smaller infarcts, and decreased fibrosis. These improvements appeared consistently in both male and female mice. Notably, conventional non-replicating Nppa (search) mRNA failed to produce similar cardioprotective effects, highlighting the self-amplifying platform's unique value.
The therapy demonstrated efficacy across challenging conditions including aged mice, atherosclerosis models using Apoe knockout mice on Western diets, metabolic syndrome models mimicking type 2 diabetes, and ischemia-reperfusion models reflecting clinical revascularization procedures.
Timing Critical for Optimal Outcomes
Treatment timing proved crucial for therapeutic success. When administered seven days post-heart attack, ejection fraction improved from about 25% to 35-40% with reduced scar area. However, strain analyses revealed incomplete recovery of left ventricular strain abnormalities, suggesting persistent long-term risks with delayed intervention.
Single-nucleus RNA sequencing of over 21,000 nuclei from mouse heart tissue revealed the therapy's broad cellular impact. Rather than targeting single cell types, treatment reshaped the entire cardiac environment by preserving cardiomyocytes and endothelial cells, limiting fibroblast expansion, and shifting Npr1-positive cell signaling toward reparative states.
Large Animal Validation and Safety Considerations
Collaboration between Texas A&M University, Columbia University, and University of Oxford extended studies to pigs. Single injections after ischemia-reperfusion injury elevated ANP levels, improved ejection fraction, normalized wall thickness, and reduced fibrosis by day 28.
However, safety concerns emerged requiring careful evaluation. Mice experienced transient weight loss during the first week post-injection, and inflammatory cytokines increased sharply in muscle tissue within 24 hours, though systemic increases remained limited. The authors emphasize that innate immune responses to saRNA necessitate thorough safety testing before clinical translation.
Clinical Translation Pathway
The intramuscular delivery approach offers practical advantages over direct cardiac interventions, being less invasive and more suitable for real-world clinical implementation. However, researchers caution this remains an animal study requiring extensive human testing.
"Our goal is to protect the heart right when it's most vulnerable," Huang noted. "If we can ease that early stress and support repair, we may be able to change the trajectory of recovery for patients."
The research represents a significant step toward more accessible regenerative cardiac therapies, though considerable development work remains before patient application becomes feasible.